Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...
Market Report by Application, Distribution Channel, Route of Administration and Company Analysis, 2025-2033" has been added ...
Enable Injections, Inc. (“Enable”) a healthcare innovation company developing and manufacturing the enFuse® On-Body Delivery ...
Skye is planning to initiate a Phase 2b clinical trial in obesity for nimacimab with ENHANZE in the middle of 2026. This study will also assess the combination of nimacimab and a GLP-1R agonist.
Hemophilia A and B involve deficiencies in coagulation factors VIII and IX, with traditional treatments requiring frequent infusions. Nonfactor therapies, including Hemlibra and rebalancing agents, ...
Abstract: Accurate tissue segmentations are the basis for volume conductor models used for simulating electric field propagation in Transcranial Brain Stimulation (TBS) and for source localization in ...
Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio amid competition among CD20xCD3 bispecific antibodies. The FDA has approved ...
Mosunetuzumab's subcutaneous formulation offers a 1-minute injection, improving convenience over the previous intravenous infusion for relapsed or refractory follicular lymphoma. The phase 1/2 GO29781 ...
Botox can cause temporary redness, swelling, tenderness, or bruising at the injection site. You may get flu-like symptoms like fever, body aches, or nausea after Botox. Botox may cause headaches, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback